- Home
- ELAB
ELAB
Elevai Labs Inc.
as 06-06-2025 4:00pm EST
Stocks
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | NEWPORT BEACH |
| Market Cap: | 6.6M | IPO Year: | 2023 |
| Target Price: | N/A | AVG Volume (30 days): | 77.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -30.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.95 - $939.96 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Elevai Labs Inc. News
ELAB Breaking Stock News: Dive into ELAB Ticker-Specific Updates for Smart Investing
GlobeNewswire
16 days ago
NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Related Sarcopenia
GlobeNewswire
24 days ago
PMGC Holdings Inc. Announces Filing of Quarterly Report on Form 10-Q
GlobeNewswire
24 days ago
PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)
GlobeNewswire
25 days ago
Northstrive Biosciences Signs Binding Term Sheet with Modulant Biosciences for Exclusive Global Animal Health Licensing of EL-22
GlobeNewswire
a month ago
RESEND - Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health
GlobeNewswire
a month ago
Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health
GlobeNewswire
a month ago
Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Phase 2 Clinical Trial
GlobeNewswire
a month ago
Northstrive Biosciences Announces Positive FDA Response Supporting A Submission of IND for a Phase 2 Clinical Trial for EL-22 in Combination with GLP-1 Receptor Agonist for Obesity Treatment
Compare ELAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ELAB Elevai Labs Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.